Enveric Biosciences financials
$1.45−1.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$8.8M | -$9.6M | -$16.4M | -$27.4M | -$64.6M | -$5.6M |
| Net income | -$12.1M | -$9.6M | -$17.5M | -$18.8M | -$49.0M | -$6.9M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-36.24 | $-228.48 | $-1455.48 | $-2340.00 | $-18664.20 | $-10710.00 |
| EBITDA | -$8.6M | -$9.3M | -$16.1M | -$19.5M | -$25.3M | -$5.5M |
| Operating cash flow | -$8.1M | -$7.7M | -$14.1M | -$17.1M | -$11.5M | -$3.9M |
| Free cash flow | -$8.1M | -$7.7M | -$14.1M | -$17.7M | -$11.6M | -$3.9M |
| Diluted shares | 0.3M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.7M | $2.2M | $2.3M | $17.7M | $17.4M | $1.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $5.1M | $3.1M | $4.3M | $19.6M | $26.7M | $4.1M |
| Total liabilities | $918.4K | $1.5M | $2.3M | $4.0M | $4.4M | $681.3K |
| Shareholders' equity | $4.2M | $1.6M | $2.0M | $14.7M | $22.3M | $3.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology